Dual Site Left Ventricular (LV) Pacing (DIVA)

This study has been completed.
Sponsor:
Collaborator:
Medtronic
Information provided by (Responsible Party):
Imran Niazi, Aurora Health Care
ClinicalTrials.gov Identifier:
NCT00944125
First received: July 17, 2009
Last updated: February 4, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to compare Dual LV (left ventricular) pacing to standard single LV pacing (BiV pacing) to see if Dual LV pacing:

  1. Improves the way the heart's left ventricle functions
  2. Decreases the number of hospital and clinic visits for heart failure related symptoms
  3. Slows the rate patients experience certain heart failure symptoms
  4. Reduces uncoordinated heart contractions

Condition Intervention
Congestive Heart Failure
LV Dysfunction
Device: Dual Site LV Pacing vs. BiV Pacing

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dual Site LV Pacing Study: Prospective Randomized Blinded Crossover Study of Patients Meeting Current CRT-D Indication to be Implanted With Dual LV Pacing Leads and Paced Chronically for at Least 6 Months Post-implant.

Resource links provided by NLM:


Further study details as provided by Aurora Health Care:

Primary Outcome Measures:
  • Change in Left Ventricular End Systolic Volume (LVESV) using the difference from baseline to three months as compared to the difference from three to six months within a patient. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: June 2009
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dual Site LV Pacing
Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
Device: Dual Site LV Pacing vs. BiV Pacing
Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
Active Comparator: BiV Pacing
Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
Device: Dual Site LV Pacing vs. BiV Pacing
Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Moderate or severe heart failure, defined as NYHA Class III-IV despite optimal pharmacological heart failure therapy
  • On heart failure medical regimen (beta blockers and ACE-I or ARB's) for at least one month before randomization
  • A 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a QRS duration > 120 ms
  • Left ventricular ejection fraction (LVEF) < 35% or equal
  • Willing and capable of undergoing the device implant procedure and participating in all testing associated with this clinical study
  • Have a life expectancy of more than 180 days, per physician discretion
  • Age 40 or above, ensuring of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Have had previous cardiac resynchronization therapy or a previous coronary venous lead
  • Unable to perform a Six-Minute Hall Walk (6MHW) Test
  • Have an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention)without CHB or planned AVJ ablation prior to randomization
  • Have an atrial tachyarrhythmia that is persistent (i.e. can be terminated with medical intervention, but does not terminate spontaneously) without planned and successful cardioversion prior to randomization (patients with unsuccessful cardioversions and no AVJ Ablation will be exited.)
  • Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis)
  • Have a mechanical tricuspid prosthesis
  • Has severe aortic or mitral stenosis
  • Enrolled in any concurrent study that may confound the results of this study
  • Patients who are or suspect they may be pregnant or plan to become pregnant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00944125

Locations
United States, Wisconsin
Aurora Cardiovascular Services
Lake Geneva, Wisconsin, United States, 53147
Aurora Cardiovascular Services
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Aurora Health Care
Medtronic
Investigators
Principal Investigator: Imran K Niazi, MD Aurora Health Care
  More Information

No publications provided

Responsible Party: Imran Niazi, Physician of Aurora Health Care, Aurora Health Care
ClinicalTrials.gov Identifier: NCT00944125     History of Changes
Other Study ID Numbers: L-08-166
Study First Received: July 17, 2009
Last Updated: February 4, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 17, 2014